Illumina Inc.
ILMN | NASDAQ
$227.97
-$8.02 (-3.40%)
Nov 2, 2026, 11:19 AM ET · Market open
Company Profile
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Jacob Thaysen | CEO, President & Director |
| Ankur Dhingra | Chief Financial Officer |
| Julie Ann Coletti | Chief Legal Officer |
| Mark Field | Chief Information Officer |
| Patricia Leckman | Senior Vice President & Chief People Officer |
| Steven Barnard | Chief Technology Officer |
| Conor Noel McNamara | Vice President of Investor Relations |
| Jakob Wedel | Chief Strategy & Corporate Development Officer |
| Kevin Carl Pegels | Chief of Global Operations |
| Scott Ericksen | Vice President & Chief Accounting Officer |
| Stephanie Campos | President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Aug 27, 2026 | 4 | Filing |
| Aug 21, 2026 | 4 | Filing |
| Aug 20, 2026 | 4 | Filing |
| Aug 17, 2026 | 8-K | Current Report |
| Aug 13, 2026 | 8-K | Current Report |
Illumina Inc.
| Country | United States |
| IPO Date | Jul 28, 2000 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 8,600 |
| CEO | Jacob Thaysen |
Contact Details
5200 Illumina Way San Diego,
California 92122 United States
Stock Details
| Ticker Symbol | ILMN |
| Exchange | NASDAQ |
| Fiscal Year | February - January |
| Reporting Currency | USD |
| CIK Code | 0001110803 |
| CUSIP Number | 452327109 |
| ISIN Number | US4523271090 |
| SIC Code | 3826 |
Recent News
- 5 hours ago / zacks.comWhy Illumina (ILMN) is a Top Growth Stock for the Long-Term
- 6 hours ago / zacks.comDon't Overlook Illumina (ILMN) International Revenue Trends While Assessing the Stock
- 3 days ago / zacks.comILMN Q3 Earnings Call Highlights Higher Guidance and Clinical Growth
- 3 days ago / zacks.comIllumina (ILMN) Reports Q3 Earnings: What Key Metrics Have to Say
- 3 days ago / seekingalpha.comIllumina, Inc. (ILMN) Q3 2026 Earnings Call Transcript
- 3 days ago / zacks.comIllumina (ILMN) Q3 Earnings Beat Estimates
- 3 days ago / marketbeat.comIllumina Q3 Earnings Call Highlights
- 3 days ago / benzinga.comIllumina Q3 2026 Earnings Call Transcript
- 3 days ago / prnewswire.comIllumina Reports Financial Results for Third Quarter of Fiscal Year 2026
- 5 days ago / zacks.comIllumina (ILMN) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Add to Watchlist
Select watchlists to add or remove ILMN